1296 related articles for article (PubMed ID: 23643661)
1. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
2. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
[TBL] [Abstract][Full Text] [Related]
3. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
4. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival.
Coutant A; Rescan C; Gilot D; Loyer P; Guguen-Guillouzo C; Baffet G
Hepatology; 2002 Nov; 36(5):1079-88. PubMed ID: 12395317
[TBL] [Abstract][Full Text] [Related]
5. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
6. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer.
Goc A; Al-Husein B; Kochuparambil ST; Liu J; Heston WW; Somanath PR
Int J Oncol; 2011 Jan; 38(1):267-77. PubMed ID: 21109949
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
8. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
[TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
10. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
11. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
Britten CD
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1395-409. PubMed ID: 23443307
[TBL] [Abstract][Full Text] [Related]
12. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
13. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
14. Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways.
Shen K; Ji L; Gong C; Ma Y; Yang L; Fan Y; Hou M; Wang Z
Biochem Pharmacol; 2012 Sep; 84(6):784-92. PubMed ID: 22771629
[TBL] [Abstract][Full Text] [Related]
15. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
Bibollet-Bahena O; Almazan G
J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
[TBL] [Abstract][Full Text] [Related]
16. Role of PI3K/Akt/mTOR and MEK/ERK pathway in Concanavalin A induced autophagy in HeLa cells.
Roy B; Pattanaik AK; Das J; Bhutia SK; Behera B; Singh P; Maiti TK
Chem Biol Interact; 2014 Mar; 210():96-102. PubMed ID: 24434245
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]